Yissum Ltd. Signs a Collaboration Agreement with Aurum Ventures MKI for the Development of Breakthrough Liver-Bypassing Oral Drug Delivery Nanotechnology

TEL AVIV, Israel--(BUSINESS WIRE)--Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today at the ILSI-Biomed Israel 2009 conference, it has signed an agreement with Aurum, Ventures MKI, the technology investment arm of Mr. Morris Kahn, for the development of a nanotechnology controlled release drug delivery platform that increases the bioavailability of orally administered lipophilic drugs. The technology was developed by Prof. Simon Benita at the Hebrew University's School of Pharmacy.